Insider buying last 90 days
No open-market insider purchases were filed for ONC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ONC insider filing, plotted on the chart in Gekko.Open ONC in Gekko
Gekko Brief
AI summaryNov 4 closeONC gains 6.4% this week as the FDA grants Priority Review to BeOne Medicines' BRUKINSA combination in first-line mantle cell lymphoma. The company is also set to present at the Jefferies Global Healthcare Conference on 17 November, and RBC Capital has reaffirmed its Buy rating with a $459 target, maintained on 28 October.
Shares close at $377.78, above both the 50-day average of $362.57 and the 200-day average of $325.33, with the 50-day above the 200-day. The GekkoIndex reads 55, placing ONC in the Neutral zone, down slightly from five days ago. The stock trades 3.8% below Gekko Fair Value of $392.55, and sits near its 52-week high of $388.66.
Earnings are due 5 November, before the open, zero days away and inside a typical 20-trading-day holding window; the prior quarter saw EPS of $2.05 against a $1.40 estimate with a 2.1% reaction, and ONC has beaten estimates in 6 of its last 8 quarters. No insider, Congress or unusual options activity appears in the current window, though an insider sale of 31,028 shares at $362.97 was filed on 27 October. Seasonally, the next 20 trading days have averaged -1.2% over 5 years, rising in 2 of them. Analyst coverage from 11 firms is unanimously rated Buy, with a consensus target of $437.57 implying 15.8% upside.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
BeOne Medicines price vs fair value
Close $377.78200-day averageGekko Fair Value $392.55
BeOne Medicines quick facts
- Market cap
- $40.37B
- P/E ratio
- 64.6
- Forward P/E
- 35.7
- EPS, TTM
- $5.59
- Revenue, TTM
- $6.13B
- Profit margin
- 10.7%
- Dividend yield
- —
- Beta
- 0.63
- Volume
- 630,017 avg 374,750
- 1-year return
- +21.1%
- Typical daily move
- ±3.1%
- Typical 20-day move
- ±9.7%
- 50-day average
- $362.57
- 200-day average
- $325.33
- Next earnings
- Nov 5 before open
- Shares outstanding
- 104.9M
BeOne Medicines swing-trade checklist
BeOne Medicines scores 1 supportive, 2 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive2 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $377.78 is above the 50-day ($362.57) and 200-day ($325.33) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
55, Neutral
Reading 55 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
3.8% below
Price is within 5% of Gekko Fair Value (3.8% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports today
Reports on Nov 5, 2026, today — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−1.2% on average
From this point in the calendar, the next 20 trading days averaged −1.2% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
BeOne Medicines stock chart and price history
BeOne Medicines closed at $377.78 on Nov 4, 2026, +21.1% over the past year, inside a 52-week range of $253.95 to $388.66.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +4.1%
- 3 months
- +14.5%
- 6 months
- +20.6%
- 1 year
- +21.1%
The full ONC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ONC in Gekko
Follow BeOne Medicines through every session
Put ONC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ONC in GekkoFree for 7 days. No credit card required.
About BeOne Medicines
BeOne Medicines focuses on finding and developing treatments for cancer patients, with reach into the United States, China, Europe and other regions. Its marketed products include BRUKINSA, a treatment for several blood cancers; TEVIMBRA, an immunotherapy used against various solid tumors and blood cancers; SYLVANT, for adults with multicentric castleman disease; BAITUOWEI, used in certain breast cancer cases; and PARTRUVIX, for various solid tumors.
Beyond these approved therapies, the company runs a broad pipeline of experimental compounds targeting different cancer pathways, alongside earlier-stage preclinical work. It has established agreements with other pharmaceutical companies, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis, reflecting collaborative ties across its research and development efforts.
The company was founded in 2010 and is headquartered in Basel, Switzerland. It previously operated under the name BeiGene, Ltd. before adopting its current name in May 2025. Its shares trade under the ticker ONC.
- Sector
- Health technology
- Website
- beonemedicines.com
BeOne Medicines GekkoIndex: the smart money zone
BeOne Medicines’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55, in the Neutral zone, down 0.2 points over five sessions.
55Neutral
Down 0.2 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 43 | +2.4% | +10.4% |
| Accumulation | 172 | +1.7% | +8.0% |
| Neutral (current zone) | 338 | +0.6% | +1.2% |
| Distribution | 83 | −0.2% | +1.8% |
| Selling | 14 | −0.7% | −4.3% |
Average ONC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ONC price, zone by zone.Track ONC in Gekko
Is BeOne Medicines stock overvalued? Gekko Fair Value
BeOne Medicines trades 3.8% below Gekko Fair Value of $392.55, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what BeOne Medicines shares are worth, recalculated every trading day.
$392.55
Gekko Fair Value, Nov 4, 2026
3.8% below fair value · About fair value
At the end of Aug 2026 the price was 9.0% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ONC in Gekko
BeOne Medicines insider and Congress trading
No open-market insider purchases were filed for BeOne Medicines, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ONC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ONC, plotted on the chart in Gekko.Open ONC in Gekko
BeOne Medicines earnings: next date and track record
BeOne Medicines reports on Nov 5, 2026, before the open (today), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, today
- EPS estimate
- $1.90
- Revenue estimate
- $1.75B
6 of 8reports beat the EPS estimate
±4.3%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- BeOne Medicines reported Q2 2026 total revenues of $1.7 billion, up 30% YoY, with GAAP EPS of $2.05 per ADS, up 144% YoY. BRUKINSA exceeded $1.2 billion in quarterly global revenues, growing 31% YoY, maintaining its position as the #1 BTK inhibitor globally. Key milestones include FDA approval of BEQALZI for mantle cell lymphoma and positive Phase III MANGROVE trial results. A $300 million U.S. manufacturing expansion was also announced.
- Guidance
- Management raised 2026 revenue guidance by $300 million and GAAP operating income guidance by $250 million on the strength of Q2 results. Global regulatory submissions for BRUKINSA in frontline MCL are planned for H2 2026, with four additional Phase III readouts expected over the next three years.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $2.05 est $1.40 | $1.71B est $1.62B | +2.1% |
| May 6, 2026 | $1.96 est $0.81 | $1.51B est $1.48B | +6.6% |
| Feb 26, 2026 | $0.58 est $1.60 | $1.50B est $1.47B | −10.0% |
| Nov 6, 2025 | $1.09 est $0.72 | $1.41B est $1.45B | −0.4% |
| Aug 6, 2025 | $0.84 est $0.48 | $1.32B est $1.44B | −2.9% |
| May 7, 2025 | $1.22 est −$0.71 | $1.12B est $1.25B | −2.4% |
| Feb 27, 2025 | −$1.43 est −$1.01 | $1.13B est $1.04B | +4.9% |
| Nov 12, 2024 | −$0.09 est −$1.04 | $1.00B | −4.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
BeOne Medicines stock forecast and analyst price targets
Analysts’ average 12-month price target for BeOne Medicines is $437.57, +15.8% from the last close, from 11 firms rating the stock in the last 90 days.
$437.57consensus 12-month target, +15.8% from the last close
Now $377.78Avg $437.57
Low $370High $466
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 27 | RBC Capital | $459 | +21.5% |
| Oct 19 | Citi | $466 | +23.4% |
| Oct 16 | Morgan Stanley | $425 | +12.5% |
| Oct 16 | Wells Fargo | $400 | +5.9% |
| Oct 16 | RBC Capital | $459 | +21.5% |
+1.2%average 20-day move after past Neutral readings
−1.2%average move over the next 20 trading days in the last 5 years
±3.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
BeOne Medicines seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, BeOne Medicines averaged −1.2% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +5.0% | 3 of 5 |
| Next 10 trading days | +3.9% | 4 of 5 |
| Next 15 trading days | −1.9% | 1 of 5 |
| Next 20 trading days | −1.2% | 2 of 5 |
| Next 30 trading days | −6.5% | 1 of 5 |
For scale, ONC’s typical 20-trading-day move in either direction is about 9.7%.
BeOne Medicines market cap and key statistics
BeOne Medicines’s market cap is $40.37B, with a P/E ratio of 64.6 and revenue of $6.13B over the last twelve months.
Valuation
- Market cap
- $40.37B
- P/E ratio
- 64.6
- Forward P/E
- 35.7
- EPS, TTM
- $5.59
- Gekko Fair Value
- $392.55
Trading
- Volume
- 630,017
- Avg volume, 20 days
- 374,750
- 52-week high
- $388.66
- 52-week low
- $253.95
- Shares outstanding
- 104.9M
Financials
- Revenue, TTM
- $6.13B
- Profit margin
- 10.7%
- Return on equity
- 14.7%
- Quarterly earnings growth, YoY
- +166.7%
Risk and income
- Beta
- 0.63
- Typical daily move
- ±3.1%
- Typical 20-day move
- ±9.7%
BeOne Medicines stock news this week
5 headlines about BeOne Medicines from the past week, newest first, each linking to the publisher.
- U.S. FDA Grants Priority Review to BeOne Medicines' BRUKINSA Combination in First-Line Mantle Cell LymphomaBusiness Wire, Nov 4
- Gear Up for BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research, Nov 3
- BeOne Medicines to Present at the Jefferies Global Healthcare ConferenceBusiness Wire, Nov 3
- BeOne Medicines (NASDAQ:ONC) Stock: Insider Xiaodong Wang Sells 31,028 SharesDefense World, Oct 31
- RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $459Moomoo, Oct 28
BeOne Medicines stock FAQ
What is BeOne Medicines’s market cap?
BeOne Medicines’s market cap is $40.37B at the Nov 4, 2026 close of $377.78, with 104.9M shares outstanding. The shares trade on a P/E ratio of 64.6.
What is the BeOne Medicines stock forecast?
The consensus analyst 12-month price target for BeOne Medicines is $437.57, +15.8% from the last close. Of the 11 firms that rated the stock in the last 90 days, 11 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is BeOne Medicines stock overvalued or undervalued?
On Gekko’s estimate BeOne Medicines is about fair value: the Nov 4, 2026 close of $377.78 is 3.8% below Gekko Fair Value of $392.55. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does BeOne Medicines report earnings next?
BeOne Medicines is expected to report on Nov 5, 2026, before the market opens (today). Analysts expect earnings of $1.90 per share on revenue of $1.75B. BeOne Medicines beat the earnings estimate in 6 of its last 8 reports, moving 4.3% on average across the report.
What is BeOne Medicines’s 52-week high and low?
BeOne Medicines’s 52-week high is $388.66 and its 52-week low is $253.95; it closed at $377.78 on Nov 4, 2026, +21.1% over the past year. Over the last five years the shares peaked at $392.30 on Nov 16, 2021.
Is BeOne Medicines stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (trend), 2 as mixed (gekkoindex and fair value) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See BeOne Medicines the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.